FGFR2/3 genomic alterations and response to Enfortumab Vedotin in metastatic urothelial carcinoma

• Elio Adib,
• Talal El‐Zarif,
• Rohit K. Jain,
• William P. Skelton IV,
• Dory Freeman,
• Catherine Curran,
• Elie W. Akl,
• Amin H. Nassar,
• Praful Ravi,
• Charlene Mantia,
• David J. Kwiatkowski,
• Toni K. Choueiri,
• Guru P. Sonpavde

Affiliations

Elio Adib

Department of Medicine, Brigham and Women's Hospital Harvard Medical School Boston Massachusetts USA

Talal El‐Zarif

Lank Center for Genitourinary Oncology Dana‐Farber Cancer Institute Boston Massachusetts USA

Rohit K. Jain

H. Lee Moffitt Cancer Center and Research Institute Tampa Florida USA

William P. Skelton IV

H. Lee Moffitt Cancer Center and Research Institute Tampa Florida USA

Dory Freeman

Lank Center for Genitourinary Oncology Dana‐Farber Cancer Institute Boston Massachusetts USA

Catherine Curran

Lank Center for Genitourinary Oncology Dana‐Farber Cancer Institute Boston Massachusetts USA

Elie W. Akl

Department of Medicine, Brigham and Women's Hospital Harvard Medical School Boston Massachusetts USA

Amin H. Nassar

Department of Medicine, Brigham and Women's Hospital Harvard Medical School Boston Massachusetts USA

Praful Ravi

Lank Center for Genitourinary Oncology Dana‐Farber Cancer Institute Boston Massachusetts USA

Charlene Mantia

Lank Center for Genitourinary Oncology Dana‐Farber Cancer Institute Boston Massachusetts USA

David J. Kwiatkowski

Department of Medicine, Brigham and Women's Hospital Harvard Medical School Boston Massachusetts USA

Toni K. Choueiri

Lank Center for Genitourinary Oncology Dana‐Farber Cancer Institute Boston Massachusetts USA

Guru P. Sonpavde

Lank Center for Genitourinary Oncology Dana‐Farber Cancer Institute Boston Massachusetts USA